Neuraxis Financials

NRXS Stock   4.73  0.10  2.16%   
Based on the key indicators related to Neuraxis' liquidity, profitability, solvency, and operating efficiency, Neuraxis is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Neuraxis' Capital Lease Obligations is comparatively stable compared to the past year. Inventory is likely to gain to about 41.6 K in 2026, whereas Other Current Liabilities is likely to drop slightly above 1.8 M in 2026.
 
Covid

Neuraxis Balance Sheet Chart

At this time, Neuraxis' Capital Lease Obligations is comparatively stable compared to the past year. Inventory is likely to gain to about 41.6 K in 2026, whereas Other Current Liabilities is likely to drop slightly above 1.8 M in 2026.
Key indicators impacting Neuraxis' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.052.02
Way Down
Slightly volatile
The essential information of the day-to-day investment outlook for Neuraxis includes many different criteria found on its balance sheet. An individual investor should monitor Neuraxis' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neuraxis.

Net Income

(7.79 Million)

  
Build AI portfolio with Neuraxis Stock

Neuraxis Earnings Geography

Please note, the imprecision that can be found in Neuraxis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neuraxis. Check Neuraxis' Beneish M Score to see the likelihood of Neuraxis' management manipulating its earnings.

Neuraxis Stock Summary

Neuraxis competes with Collplant Biotechnologies, Neurosense Therapeutics, Exicure, Klotho Neurosciences, and Enlivex Therapeutics. Neuraxis is entity of United States. It is traded as Stock on NYSE MKT exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNYSE MKT Exchange
ISINUS64134X2018
Business Address11611 North Meridian
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteneuraxis.com
Phone812 689 0791

Neuraxis Key Financial Ratios

Neuraxis Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets760.5K1.5M509.5K4.8M5.5M5.7M
Other Current Liab593.2K4.8M409.3K1.6M1.8M1.8M
Net Debt118.4K345.1K145.7K(3.2M)(2.9M)(2.8M)
Retained Earnings(29.2M)(33.9M)(48.6M)(56.8M)(51.1M)(53.7M)
Accounts Payable483.8K1.6M1.2M596.9K686.5K889.2K
Cash320.9K253.7K78.6K3.7M4.3M4.5M
Net Receivables115.3K174.4K73.2K244.6K220.2K147.0K
Inventory39.2K48.1K21.2K44.3K39.9K41.6K
Other Current Assets15.7K726.069.7K280.4K322.4K338.5K
Total Liab1.6M7.1M1.9M2.7M3.1M3.2M
Net Invested Capital(523.6K)(5.1M)(1.3M)2.2M2.6M2.7M
Short Long Term Debt250.4K489.2K148.1K154.2K138.7K190.9K
Total Current Assets491.0K477.0K242.6K4.3M4.9M5.2M
Capital Stock2.6K2.6K6.5K11.3K13.0K13.6K
Net Working Capital(933.8K)(6.5M)(1.6M)1.8M2.1M2.2M
Short Term Debt278.0K522.6K197.2K216.9K249.4K305.6K
Intangible Assets24.0K77.6K108.1K96.6K111.1K73.1K
Common Stock2.6K2.0K6.5K7.0K8.0K4.5K

Neuraxis Key Income Statement Accounts

The reason investors look at the income statement is to determine what Neuraxis' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202120222023202420252026 (projected)
Net Interest Income(36.9K)(2.7M)(5.4M)(531.5K)(478.4K)(502.3K)
Interest Expense36.9K417.6K5.4M300.7K345.8K328.5K
Total Revenue2.7M2.7M2.5M2.7M3.1M2.7M
Gross Profit2.3M2.4M2.2M2.3M2.7M2.3M
Operating Income(3.0M)(3.4M)(6.7M)(7.2M)(6.4M)(6.8M)
Ebit(3.0M)(4.4M)(9.3M)(7.9M)(7.1M)(7.5M)
Research Development203.4K225.6K169.3K206.1K237.0K213.7K
Ebitda(3.0M)(4.3M)(9.2M)(7.9M)(7.1M)(7.5M)
Cost Of Revenue467.7K297.1K303.3K362.0K325.8K305.8K
Income Before Tax(3.0M)(4.8M)(14.6M)(8.2M)(7.4M)(7.8M)
Net Income(3.0M)(4.8M)(14.6M)(8.2M)(7.4M)(7.8M)
Income Tax Expense45.2K429.6K5.4M(8.2M)(7.4M)(7.0M)

Neuraxis Key Cash Accounts

202120222023202420252026 (projected)
Change To Inventory67.7K(9.0K)26.9K(32.5K)(29.3K)(27.8K)
Investments(1.4K)(61.2K)(71.8K)(27.8K)(25.0K)(26.2K)
Change In Cash(1.6M)(67.2K)(175.1K)3.6M4.2M4.4M
Net Borrowings151.1K3.2M2.1M4.7M5.4M5.6M
Free Cash Flow(2.2M)(2.4M)(6.8M)(6.1M)(5.5M)(5.8M)
Depreciation36.7K37.1K40.7K37.8K43.5K41.4K
Other Non Cash Items22.8K1.1M7.8M559.8K643.8K611.6K
Capital Expenditures1.4K61.2K71.8K27.8K31.9K41.8K
Net Income(3.0M)(4.8M)(14.6M)(8.2M)(7.4M)(7.8M)
End Period Cash Flow320.9K253.7K78.6K3.7M4.3M4.5M

Neuraxis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Neuraxis's current stock value. Our valuation model uses many indicators to compare Neuraxis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuraxis competition to find correlations between indicators driving Neuraxis's intrinsic value. More Info.
Neuraxis is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Neuraxis' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuraxis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Neuraxis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuraxis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuraxis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median.
For more information on how to buy Neuraxis Stock please use our How to Invest in Neuraxis guide.Enterprise Value is likely to gain to about 16.5 M in 2026, whereas Selling General Administrative is likely to drop slightly above 7 M in 2026.
 2023 2024 2025 2026 (projected)
Interest Expense5.4M300.7K345.8K328.5K
Depreciation And Amortization40.7K37.8K43.5K41.4K

Neuraxis fundamental ratios Correlations

0.370.120.040.64-0.10.77-0.16-0.94-0.5-0.110.990.190.990.20.350.90.94-0.050.970.550.070.650.79-0.320.99
0.370.840.81-0.38-0.70.19-0.72-0.11-0.510.610.30.840.3-0.40.850.530.53-0.590.20.470.83-0.370.540.660.26
0.120.840.98-0.67-0.54-0.18-0.550.16-0.340.760.021.00.02-0.340.860.110.19-0.45-0.070.210.98-0.660.160.87-0.02
0.040.810.98-0.74-0.68-0.3-0.680.24-0.450.88-0.050.96-0.05-0.530.90.070.17-0.6-0.10.291.0-0.730.140.87-0.09
0.64-0.38-0.67-0.740.460.740.42-0.820.01-0.750.7-0.610.70.54-0.450.550.50.440.730.14-0.721.00.42-0.890.73
-0.1-0.7-0.54-0.680.460.191.0-0.120.83-0.84-0.09-0.53-0.090.9-0.79-0.33-0.390.99-0.11-0.69-0.690.46-0.41-0.46-0.03
0.770.19-0.18-0.30.740.190.15-0.87-0.14-0.50.79-0.10.790.520.010.720.680.240.750.42-0.260.750.8-0.520.8
-0.16-0.72-0.55-0.680.421.00.15-0.070.85-0.83-0.15-0.54-0.150.88-0.81-0.39-0.450.98-0.16-0.71-0.690.42-0.45-0.44-0.08
-0.94-0.110.160.24-0.82-0.12-0.87-0.070.360.37-0.950.08-0.95-0.41-0.08-0.81-0.83-0.15-0.95-0.470.22-0.83-0.740.57-0.97
-0.5-0.51-0.34-0.450.010.83-0.140.850.36-0.64-0.52-0.37-0.520.65-0.74-0.57-0.690.84-0.57-0.9-0.470.01-0.67-0.04-0.46
-0.110.610.760.88-0.75-0.84-0.5-0.830.37-0.64-0.150.74-0.15-0.820.85-0.030.1-0.84-0.140.440.87-0.750.090.7-0.21
0.990.30.02-0.050.7-0.090.79-0.15-0.95-0.52-0.150.091.00.190.290.920.95-0.060.980.57-0.020.710.8-0.411.0
0.190.841.00.96-0.61-0.53-0.1-0.540.08-0.370.740.090.09-0.30.880.170.25-0.430.010.260.97-0.60.240.820.06
0.990.30.02-0.050.7-0.090.79-0.15-0.95-0.52-0.151.00.090.190.290.920.95-0.060.980.57-0.020.710.8-0.411.0
0.2-0.4-0.34-0.530.540.90.520.88-0.410.65-0.820.19-0.30.19-0.56-0.05-0.110.940.14-0.45-0.520.54-0.06-0.420.25
0.350.850.860.9-0.45-0.790.01-0.81-0.08-0.740.850.290.880.29-0.560.380.5-0.740.270.660.91-0.440.530.580.24
0.90.530.110.070.55-0.330.72-0.39-0.81-0.57-0.030.920.170.92-0.050.380.97-0.280.870.60.110.560.82-0.220.9
0.940.530.190.170.5-0.390.68-0.45-0.83-0.690.10.950.250.95-0.110.50.97-0.350.920.70.20.520.86-0.210.92
-0.05-0.59-0.45-0.60.440.990.240.98-0.150.84-0.84-0.06-0.43-0.060.94-0.74-0.28-0.35-0.1-0.7-0.610.43-0.38-0.380.01
0.970.2-0.07-0.10.73-0.110.75-0.16-0.95-0.57-0.140.980.010.980.140.270.870.92-0.10.63-0.080.740.8-0.50.98
0.550.470.210.290.14-0.690.42-0.71-0.47-0.90.440.570.260.57-0.450.660.60.7-0.70.630.310.140.87-0.150.53
0.070.830.981.0-0.72-0.69-0.26-0.690.22-0.470.87-0.020.97-0.02-0.520.910.110.2-0.61-0.080.31-0.710.180.86-0.06
0.65-0.37-0.66-0.731.00.460.750.42-0.830.01-0.750.71-0.60.710.54-0.440.560.520.430.740.14-0.710.43-0.880.74
0.790.540.160.140.42-0.410.8-0.45-0.74-0.670.090.80.240.8-0.060.530.820.86-0.380.80.870.180.43-0.250.78
-0.320.660.870.87-0.89-0.46-0.52-0.440.57-0.040.7-0.410.82-0.41-0.420.58-0.22-0.21-0.38-0.5-0.150.86-0.88-0.25-0.44
0.990.26-0.02-0.090.73-0.030.8-0.08-0.97-0.46-0.211.00.061.00.250.240.90.920.010.980.53-0.060.740.78-0.44
Click cells to compare fundamentals

Neuraxis Account Relationship Matchups

Neuraxis fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets760.5K1.5M509.5K4.8M5.5M5.7M
Other Current Liab593.2K4.8M409.3K1.6M1.8M1.8M
Net Debt118.4K345.1K145.7K(3.2M)(2.9M)(2.8M)
Retained Earnings(29.2M)(33.9M)(48.6M)(56.8M)(51.1M)(53.7M)
Accounts Payable483.8K1.6M1.2M596.9K686.5K889.2K
Cash320.9K253.7K78.6K3.7M4.3M4.5M
Net Receivables115.3K174.4K73.2K244.6K220.2K147.0K
Inventory39.2K48.1K21.2K44.3K39.9K41.6K
Other Current Assets15.7K726.069.7K280.4K322.4K338.5K
Total Liab1.6M7.1M1.9M2.7M3.1M3.2M
Net Invested Capital(523.6K)(5.1M)(1.3M)2.2M2.6M2.7M
Short Long Term Debt250.4K489.2K148.1K154.2K138.7K190.9K
Total Current Assets491.0K477.0K242.6K4.3M4.9M5.2M
Capital Stock2.6K2.6K6.5K11.3K13.0K13.6K
Net Working Capital(933.8K)(6.5M)(1.6M)1.8M2.1M2.2M
Short Term Debt278.0K522.6K197.2K216.9K249.4K305.6K
Intangible Assets24.0K77.6K108.1K96.6K111.1K73.1K
Common Stock2.6K2.0K6.5K7.0K8.0K4.5K
Today, most investors in Neuraxis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuraxis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neuraxis growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0455

At this time, Neuraxis' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Neuraxis January 9, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Neuraxis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuraxis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuraxis based on widely used predictive technical indicators. In general, we focus on analyzing Neuraxis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuraxis's daily price indicators and compare them against related drivers.

Additional Tools for Neuraxis Stock Analysis

When running Neuraxis' price analysis, check to measure Neuraxis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuraxis is operating at the current time. Most of Neuraxis' value examination focuses on studying past and present price action to predict the probability of Neuraxis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuraxis' price. Additionally, you may evaluate how the addition of Neuraxis to your portfolios can decrease your overall portfolio volatility.